Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switching to Xanomeline/Trospium in Schizophrenia
NCT06924255Phase 4Not yet recruiting
- Sponsor
- Collaborative Neuroscience Research
- Start
- Apr 2025
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of trospium in schizophrenia, sponsored by Collaborative Neuroscience Research. Planned start Apr 2025; status: not yet recruiting.
02
Drugs
trospium
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT06924255.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06924255.